Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 91Melanoma 74Squamous Cell Carcinoma of Head and Neck 47Neoplasms 44Neoplasm Metastasis 43Lung Neoplasms 37Carcinoma, Renal Cell 36Colorectal Neoplasms 35Breast Neoplasms 34Triple Negative Breast Neoplasms 30Stomach Neoplasms 26Carcinoma, Transitional Cell 26Ovarian Neoplasms 25Head and Neck Neoplasms 24Parkinson Disease 4, Autosomal Dominant Lewy Body 21Esophageal Neoplasms 20Pancreatic Neoplasms 18Uterine Cervical Neoplasms 17Urinary Bladder Neoplasms 16Endometrial Neoplasms 16Small Cell Lung Carcinoma 15Carcinoma, Hepatocellular 15Sarcoma 13Recurrence 12Glioblastoma 12Carcinoma 12Prostatic Neoplasms 11Lymphoma 11Mesothelioma 9Carcinoma, Merkel Cell 9

Interventions

trifluridine tipiracil drug combination 1pembrolizumab 1Trifluridine 1Standard of Care 1Injections 1HMPL-013 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Advanced/Metastatic Solid Tumors × pembrolizumab × Clear all
NCT05405595 2026-01-07

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Adagene Inc

Phase 1/2 Recruiting
186 enrolled
Other solid neoplasm

Advanced/Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡